Wolfgang Janni

Summary

Country: Germany

Publications

  1. pmc Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy
    Sabine Kasimir-Bauer
    Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg Essen, Hufelandstrasse 55, D 45122, Essen, Germany
    Breast Cancer Res 18:20. 2016
  2. pmc Anti-Mullerian-hormone levels during pregnancy and postpartum
    Angela Köninger
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Reprod Biol Endocrinol 11:60. 2013
  3. pmc LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival
    Jan Dominik Kuhlmann
    Department of Gynecology and Obstetrics, University Hospital of Essen, Hufelandstrasse 55, Essen, D 45122, Germany
    BMC Cancer 12:325. 2012
  4. pmc Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
    Sabine Kasimir-Bauer
    Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg Essen, D 45122 Essen, Germany
    Breast Cancer Res 14:R15. 2012
  5. pmc Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
    Volkmar Muller
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20241 Hamburg, Germany
    Breast Cancer Res 13:R71. 2011
  6. pmc Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
    Tanja Fehm
    Department of Gynecology and Obstetrics, Calwer Strasse 7, University Hospital of Tuebingen, D 72076 Tuebingen, Germany
    Breast Cancer Res 11:R59. 2009
  7. pmc Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer
    Heidi Schwarzenbach
    Institute of Tumor Biology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, Hamburg, 20246, Germany
    Breast Cancer Res 11:R71. 2009
  8. pmc Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Breast Cancer Res 11:R46. 2009
  9. pmc Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression
    Carina Roth
    Institute of Tumor Biology, University Medical Center Hamburg Eppendorf, Germany
    BMC Cancer 11:4. 2011
  10. doi request reprint Prognostic relevance of the AQP5 -1364C>A polymorphism in primary breast cancer
    Sabine Kasimir-Bauer
    Klinik fur Frauenheilkunde und Geburtshilfe, Universitatsklinikum Essen, Hufelandstr 55, D 45122 Essen, Germany
    Mol Med Rep 2:645-50. 2009

Collaborators

Detail Information

Publications51

  1. pmc Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy
    Sabine Kasimir-Bauer
    Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg Essen, Hufelandstrasse 55, D 45122, Essen, Germany
    Breast Cancer Res 18:20. 2016
    ....
  2. pmc Anti-Mullerian-hormone levels during pregnancy and postpartum
    Angela Köninger
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Reprod Biol Endocrinol 11:60. 2013
    ..In this study we analyzed AMH in a cohort of pregnant women without fertility impairment to determine age-dependent decline and possible AMH fluctuations during pregnancy and postpartum...
  3. pmc LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival
    Jan Dominik Kuhlmann
    Department of Gynecology and Obstetrics, University Hospital of Essen, Hufelandstrasse 55, Essen, D 45122, Germany
    BMC Cancer 12:325. 2012
    ....
  4. pmc Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
    Sabine Kasimir-Bauer
    Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg Essen, D 45122 Essen, Germany
    Breast Cancer Res 14:R15. 2012
    ..Data were correlated with the presence of disseminated tumor cells (DTC) in the bone marrow (BM) and with clinicopathological data of the patients...
  5. pmc Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
    Volkmar Muller
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20241 Hamburg, Germany
    Breast Cancer Res 13:R71. 2011
    ..The aim of the study was to investigate whether serum concentrations of TIMP-1 and CAIX are associated with the detection of CTC in metastatic breast cancer...
  6. pmc Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
    Tanja Fehm
    Department of Gynecology and Obstetrics, Calwer Strasse 7, University Hospital of Tuebingen, D 72076 Tuebingen, Germany
    Breast Cancer Res 11:R59. 2009
    ....
  7. pmc Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer
    Heidi Schwarzenbach
    Institute of Tumor Biology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, Hamburg, 20246, Germany
    Breast Cancer Res 11:R71. 2009
    ..Here we investigated whether the detection of this DNA is related to bone marrow (BM) micrometastasis and tumor recurrence in breast cancer patients...
  8. pmc Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Breast Cancer Res 11:R46. 2009
    ....
  9. pmc Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression
    Carina Roth
    Institute of Tumor Biology, University Medical Center Hamburg Eppendorf, Germany
    BMC Cancer 11:4. 2011
    ....
  10. doi request reprint Prognostic relevance of the AQP5 -1364C>A polymorphism in primary breast cancer
    Sabine Kasimir-Bauer
    Klinik fur Frauenheilkunde und Geburtshilfe, Universitatsklinikum Essen, Hufelandstr 55, D 45122 Essen, Germany
    Mol Med Rep 2:645-50. 2009
    ..Further investigations must include more than one AQP as well as factors promoting angiogenesis to elucidate the different modes of tumor cell dissemination...
  11. doi request reprint Circulating tumor cells as markers for cancer risk assessment and treatment monitoring
    Sabine Kasimir-Bauer
    Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg Essen, Essen, Germany
    Mol Diagn Ther 13:209-15. 2009
    ..The majority of studies published on CTCs to date have been related to primary and metastatic breast cancer; therefore, this article mainly addresses the role of CTCs in breast cancer...
  12. ncbi request reprint The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms
    Martin Heubner
    Institute of Pharmacogenetics, Medical Faculty, University of Duisburg Essen, Essen, Germany
    Oncol Res 18:343-7. 2010
    ..If confirmed in a larger, independent collective, our findings would have important relevance with respect to the clinical consequences for the primary chemotherapy of ovarian cancer patients...
  13. ncbi request reprint Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells
    Alexander König
    Department of Gynecology and Obstetrics, Ludwig Maximilians University, Munich, Germany
    Anticancer Res 36:3123-30. 2016
    ..Circulating tumor cells (CTCs) in women with breast cancer are an indication of prognosis before starting systemic treatment. The aim of this study was the evaluation of cytokine profiles as marker for CTC involvement...
  14. doi request reprint Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients
    Brigitte Rack
    Department of Gynecology and Obstetrics, Ludwig Maximilians University, Munich, Germany
    Oncology 90:232-8. 2016
    ..The aim of this study was to measure the human epidermal growth factor receptor 2 (HER2) status of disseminated tumor cells (DTCs) from bone marrow (BM) aspirates and to assess correspondence or discrepancy with the primary tumor...
  15. doi request reprint The haplotype of two FSHR polymorphisms in ovarian cancer--a potential role of ethnology in risk modification
    Martin Heubner
    Institute of Pharmacogenetics, Medical Faculty, University of Duisburg Essen, Germany
    Gynecol Oncol 112:486-9. 2009
    ..In this study we investigated the impact of this haplotype regarding the risk to develop ovarian cancer as well as possible effects upon the clinical course in a Caucasian patient sample...
  16. doi request reprint Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II
    Lukas Schwentner
    Department of Gynecology and Obstetrics, University Ulm, Prittwitzstraße 43, 89075, Ulm, Germany
    Support Care Cancer 24:2759-66. 2016
    ..This study examined which patient- and physician-related factors influence guideline violations in adjuvant chemotherapy...
  17. pmc Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial
    Malgorzata Banys
    Department of Gynecology and Obstetrics, Heinrich Heine University of Dusseldorf, Moorenstr, 5, 40225, Dusseldorf, Germany
    BMC Cancer 13:480. 2013
    ..This controlled randomized open-label multi-center study aimed to investigate the influence of zoledronic acid (ZOL) on DTC and survival of breast cancer patients (Clinical Trial Registration Number: NCT00172068)...
  18. doi request reprint Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University of Essen, Hufelandstrase 55, 45122 Essen, Germany
    Gynecol Oncol 122:356-60. 2011
    ..It was the purpose of the present study (1) to reevaluate the ER/PR expression by CTCs and (2) to compare the hormone receptor status expression profile of CTCs with the primary tumor...
  19. ncbi request reprint Circulating 20S proteasome in patients with non-metastasized breast cancer
    Oliver Hoffmann
    Clinic of Obstetrics and Gynecology, Medical Faculty, University of Duisburg Essen, Hufelandstr 55, D 45147 Essen, Germany
    Anticancer Res 31:2197-201. 2011
    ..We tested the hypothesis that the plasma c-proteasome concentration is a biomarker associated with tumor stage and nodal status in patients with the primary diagnosis of non-metastatic breast cancer...
  20. doi request reprint Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy
    Jan Dominik Kuhlmann
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Essen, Germany
    Genes Chromosomes Cancer 50:598-605. 2011
    ..05) and after chemotherapy (P = 0.022). Conclusively, our data suggest that allelic loss at D6S1581 (proximal to M6P/IGF2R locus) serves as a molecular biomarker for the presence of DTC in the BM before and after chemotherapy...
  21. doi request reprint Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Essen, Germany
    Int J Gynecol Cancer 21:822-30. 2011
    ..Results were compared with detection of DTC in BM...
  22. ncbi request reprint Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study
    Oliver Hoffmann
    Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg Essen, Hufelandstrasse 55, D 45122 Essen, Germany
    Anticancer Res 31:3623-8. 2011
    ..The purpose of our study was to: i) analyze the presence of DTCs in the BM of breast cancer patients 2-10 years after first diagnosis of cancer, and ii) to study the effect of ibandronate on DTCs in those patients with DTC persistence...
  23. doi request reprint Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients
    Pauline Wimberger
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Essen, Germany
    Int J Cancer 128:2572-80. 2011
    ..Serum DNA levels together with BM status for DTCs have the potential to become suitable biomarkers to predict the prognosis of ovarian cancer patients undergoing platinum-based chemotherapy...
  24. doi request reprint EpCAM-autoantibody levels in the course of disease of ovarian cancer patients
    Martin Heubner
    Clinic of Obstetrics and Gynaecology, Medical Faculty, University of Duisburg Essen, Essen, Germany
    Med Oncol 28:626-30. 2011
    ..We observed an increase in AAB-levels during the first-line treatment of patients with ovarian cancer. EpCAM-AAB-levels after first-line treatment appear to correlate with macroscopic tumor residuals after initial surgery...
  25. ncbi request reprint The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer
    Martin Heubner
    Institute of Pharmacogenetics, University of Duisburg Essen, Hufelandstr 55, 45147 Essen, Germany
    Anticancer Res 29:3449-52. 2009
    ..The gene L1C was screened for single nucleotide polymorphisms (SNPs) which could impact upon EOC risk or disease progression...
  26. doi request reprint Placental growth factor: a predictive marker for preeclampsia?
    Markus Schmidt
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Essen, Germany
    Gynakol Geburtshilfliche Rundsch 49:94-9. 2009
    ..This study was designed to answer the question whether the measurement of PLGF at the beginning of the second trimester might be a predictive factor for the appearance of preeclampsia...
  27. doi request reprint Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients
    Brigitte Rack
    Department of Gynecology and Obstetrics, Klinikum Innenstadt, Ludwig Maximilians Universitaet Muenchen, Maistr 11, 80337 Munich, Germany
    Arch Gynecol Obstet 285:485-92. 2012
    ..We tested the efficacy of trastuzumab in clearing HER2/neu-positive ITC from the marrow of patients completing primary treatment...
  28. doi request reprint Detection of circulating trophoblast particles in peripheral maternal blood in preeclampsia complicated pregnancies
    Markus Schmidt
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Essen, Germany
    Hypertens Pregnancy 27:131-42. 2008
    ..Data on trophoblast particles in peripheral maternal circulation are rare. Applying a new enrichment technique, Oncoquick, we evaluated the number of trophoblast particles in maternal blood in preeclamptic and non-preeclamptic pregnancies...
  29. ncbi request reprint Which patient- and physician-related factors are associated with guideline adherent initiation of adjuvant endocrine therapy? Results of the prospective multi-centre cohort study BRENDA II
    Tanja Stüber
    Department of Gynecology and Obstetrics, University Wurzburg, Joseph Schneider Str 4, 97080, Wurzburg, Germany
    Breast Cancer . 2016
    ..We analysed factors that might influence patients' and physicians' decisions against the initiation of guideline adherent adjuvant endocrine therapy (ET)...
  30. pmc Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Essen, Germany
    BMC Cancer 16:522. 2016
    ..Here we compared HER2/ER/PR expression profiles of primary tumors, metastases and CTCs...
  31. ncbi request reprint Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival
    Sabine Kasimir-Bauer
    University of Essen Medical School, Department of Internal Medicine Cancer Research, West German Cancer Center, Essen, Germany
    Oncol Rep 10:475-82. 2003
    ..Thus, we conclude that the detection of CK+ cells should be added to routine pathology and for tumour marker determination, studies should focus on Cyfra 21-1 and TPA...
  32. ncbi request reprint Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial
    Philip Hepp
    Department of Gynecology and Obstetrics, Helios University Hospital Wuppertal, University Witten Herdecke, Wuppertal, Germany
    Anticancer Res 36:4771-6. 2016
    ..29. Here we report the association of these two prognostic markers before and immediately after chemotherapy (CHT), as well as after 2 and 5 years of follow-up...
  33. doi request reprint Comparison of seroma production in breast conserving surgery with or without intraoperative radiotherapy as tumour bed boost
    Florian Ebner
    Klinik fur Frauenheilkunde und Geburtshilfe, Universitat Ulm, Prittwitzstr 43, 89075, Ulm, Germany
    Arch Gynecol Obstet 294:861-6. 2016
    ..Therefore, this analysis compares seroma production in patients with breast conserving surgery with or without IORT as tumour bed boost during breast conserving surgery...
  34. pmc Sentinel node biopsy and axillary dissection in breast cancer: the evidence and its limits
    Wolfgang Janni
    Department of Obstetrics and Gynecology, Ulm University Medical Center, Department of Gynecology and Obstetrics, Hospital Esslingen, Department of Gynecology and Obstetrics, Dusseldorf University Hospital
    Dtsch Arztebl Int 111:244-9. 2014
    ..The optimal role of sentinel node biopsy (SNB) in neo-adjuvant therapy is currently under discussion...
  35. doi request reprint The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer
    Martin Heubner
    Clinic of Obstetrics and Gynaecology, Medical Faculty, University of Duisburg Essen, Germany
    Gynecol Oncol 120:233-8. 2011
    ..We tested the hypothesis that the c-proteasome plasma concentration is a biomarker associated with the clinical course of ovarian cancer patients...
  36. doi request reprint Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies
    Mitra Tewes
    Department of Internal Medicine Cancer Research, University Hospital Essen, University of Duisburg Essen, 45122, Essen, Germany
    Breast Cancer Res Treat 115:581-90. 2009
    ..We analyzed circulating tumor cells (CTC) in blood of metastatic breast cancer patients (n = 42) and determined the ability of this method to predict therapy response...
  37. ncbi request reprint Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia
    Sabine Kasimir-Bauer
    Departments of Internal Medicine Cancer Research, University of Essen, Medical School, West German Cancer Center, Essen, Germany
    Exp Hematol 30:1302-8. 2002
    ..Resistance to chemotherapy-induced apoptosis and a multidrug-resistance phenotype is the major problem in the treatment of acute myeloid leukemia (AML)...
  38. ncbi request reprint Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer
    Martin Heubner
    Institute of Pharmacogenetics, Medical Faculty, University of Duisburg Essen, Essen Germany
    Int J Biol Markers 24:223-9. 2009
    ..Recently, a novel regulatory single nucleotide polymorphism (-938C>A) in the inhibitory P2 BCL2 promoter was described. In this study we investigated its potential association with survival in epithelial ovarian cancer...
  39. ncbi request reprint Influence of Circulating Tumour Cells on Production of IL-1α, IL-1β and IL-12 in Sera of Patients with Primary Diagnosis of Breast Cancer Before Treatment
    Theresa Vilsmaier
    Department of Gynecology and Obstetrics, Ludwig Maximilian University, Munich, Germany
    Anticancer Res 36:5227-5236. 2016
    ..Determination of CTCs with the CellSearch System (Veridex, Raritan, NJ, USA) is a valuable but time-consuming and costly method. Therefore, the aim of this study was to evaluate cytokine profiles as a marker for CTC involvement...
  40. doi request reprint Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer
    Tanja Fehm
    Department of Gynecology and Obstetrics, University Hospital Dusseldorf, University of Dusseldorf, Germany
    Int J Gynecol Cancer 23:839-45. 2013
    ..Recent studies demonstrated that DTCs may serve as a prognostic factor in ovarian cancer. The aim of this 3-center study was to evaluate the impact of BM status on survival in a large cohort of patients with ovarian cancer...
  41. doi request reprint mRNA of placental origin in maternal serum of women with normal and preeclamptic pregnancies
    Markus Schmidt
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Essen, Germany
    Fetal Diagn Ther 25:269-76. 2009
    ..We quantified placenta-specific mRNA from maternal blood to evaluate differences in normal and preeclamptic pregnancies...
  42. ncbi request reprint Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer
    Pauline Wimberger
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Hufelandstrasse 55, D 45122 Essen, Germany
    Gynecol Oncol 107:331-8. 2007
    ....
  43. doi request reprint Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
    Jessica Salmen
    Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
    Breast Cancer Res Treat 148:143-51. 2014
    ..The significantly greater prognostic value in node-positive and high-grade tumors suggests a greater role in the progression of advanced and aggressive tumors. ..
  44. ncbi request reprint Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer
    Brigitte Rack
    Department of Gynecology and Obstetrics, Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe, Campus Innenstadt, Ludwig Maximilians Universitaet, Muenchen, Germany
    Anticancer Res 30:1807-13. 2010
    ..The goal of this study was to investigate the therapeutic efficacy of zoledronate on the persistence of ITC...
  45. ncbi request reprint Altered angiogenesis in preeclampsia: evaluation of a new test system for measuring placental growth factor
    Markus Schmidt
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Essen, Germany
    Clin Chem Lab Med 45:1504-10. 2007
    ..In the present study, we demonstrated the assay characteristics by measurement of PLGF expression in normal and preeclamptic pregnancies as compared to an established research kit...
  46. ncbi request reprint Peri-operative filtration of disseminated cytokeratin positive cells in patients with colorectal liver metastasis
    Nils R Fruhauf
    Department of General Surgery and Transplantation, University of Essen, Hufelandstrasse 55, 45147, Essen, Germany
    Langenbecks Arch Surg 390:15-20. 2005
    ..As prevention of cell dissemination is barely obtainable, alternative concepts have to be discussed...
  47. pmc Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study
    Paul Gaß
    Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
    Breast Care (Basel) 11:315-322. 2016
    ..The aim of this study was to identify the patient population for whom this issue may bear relevance...
  48. doi request reprint Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients
    Alexander Hein
    Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen EMN, Friedrich Alexander, Erlangen University Hospital University of Erlangen Nuremberg, Universitätsstrasse 21 23, 91054, Erlangen, Germany
    Breast Cancer Res Treat 158:59-65. 2016
    ..With the instrument's high specificity, its application in a large cohort of patients appears to be feasible, and the workload for reassessing the patients is limited. ..
  49. pmc The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
    Peter Widschwendter
    Department of Gynecology and Obstetrics, University Ulm, Prittwitzstraße 43, 89075, Ulm, Germany
    Breast Cancer Res 17:129. 2015
    ..Obese breast cancer patients have worse prognosis than normal weight patients, but the level at which obesity is prognostically unfavorable is unclear...
  50. pmc Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9,156 patients
    Lukas Schwentner
    Department of Gynecology and Obstetrics, University Ulm, Prittwitzstraße 43, Ulm 89075, Germany
    BMC Cancer 13:487. 2013
    ..We evaluated possible differences in survival in TNBC by age and by the extent to which evidence-based treatment guidelines were adhered...
  51. doi request reprint HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
    Tanja Fehm
    Department of Gynecology and Obstetrics, University of Tubingen, Calwer Strasse 7, 72076, Tubingen, Germany
    Breast Cancer Res Treat 124:403-12. 2010
    ..Therefore, it will be mandatory to correlate the assay-dependent HER2 status of CTCs to the clinical response on HER2-targeted therapies...